GCSF Guidelines Northern Cancer Alliance

This is a guideline for the use of granulocyte-colony stimulating factor (G-CSF) in adult oncology and haematology patients


GCSF Guidelines Northern Cancer Alliance - cover page
Category
Other
Document type
Other
Language
English
Pages
11
File format
PDF
File size
525 KB
Published
20 October, 2023
Updated
20 October, 2023
MD5 checksum
C741B399CB3E1B1E3B4A3062D43A2E1F

About this manual

This document provides evidence-based guidance from the Northern Cancer Alliance regarding the use of Granulocyte-Colony Stimulating Factor (G-CSF) for adult patients with cancer and haematological conditions. It outlines specific criteria for prescribing G-CSF, including indications for chemotherapy support, treatment for severe neutropenic sepsis, and peripheral blood stem cell mobilisation. The guidelines cover both primary and secondary prophylaxis strategies.

What's inside

  • Introduction
  • Indications for G-CSF use
  • Criteria for G-CSF prescribing
  • Chemotherapy support for regimens with curative intent
  • Supportive therapy for severe neutropenic sepsis
  • Peripheral blood stem cell mobilisation
  • Peripheral blood stem cell transplantation
  • Approval to prescribe G-CSF
  • Dosage and administration guidelines
  • References

Frequently asked questions

When should G-CSF be started after chemotherapy?

G-CSF should be started not less than 24 hours and not more than 72 hours after cytotoxic treatment is completed.

How long should daily G-CSF injections continue?

Injections should continue until the neutrophil count has recovered to > 1.0 x 10 9/L on two consecutive days.

Which G-CSF is recommended for primary prophylaxis in the CNTW Area Team?

The G-CSF of choice is daily G-CSF in the form of the biosimilar Filgrastim.

Download PDF (525 KB)

Also Manuals